Metabolism and Disease: From Obesity and Diabetes to Cancer and Immunometabolism
The question this article answers
The preceding pillars described how cells acquire, convert and spend carbon, nitrogen and reducing equivalents. This one asks a different question: what has to be true before a metabolic observation becomes a disease mechanism?
That question is not rhetorical. Most of the field's disagreements are not about biology. They are about which tissue was measured, over what period, and whether the measured quantity is the one the claim requires. A fasting glucose, a body weight, a liver enzyme and a tumour volume are all convenient, and each of them is a proxy for something the disease actually is.
Three disciplines follow, and they organise everything below.
Tissue. Whole-body glucose reflects the sum of hepatic output, muscle disposal, adipose release and renal handling. Two opposite tissue defects can produce the same number, and a drug that fixes the number can act on either.
Timescale. Insulin resistance develops over years; cytokine secretion changes in minutes; fibrosis over months. An acute perturbation rarely models a chronic set point, and a chronic model rarely isolates a mechanism.
Set point versus response. Many metabolic diseases are best described as a shifted set point with an intact acute response. Treating a set-point disease with an acute stimulus, or inferring a set-point shift from one stimulus, produces claims that replicate in the lab and fail in the clinic.
Boundary of this article
This article owns the disease-facing layer: which tissue lost control of which flux, and what evidence each disease claim requires. It does not re-teach measurement: glucose and lactate flux belong to the glucose pillar, lipid species and storage to the lipid pillar, nitrogen and one-carbon to the amino acid pillar, and mitochondrial programmes to the mitochondrial pillar. Where those pillars established a readout rule, this article cites it rather than repeating it.
Tumour-cell-intrinsic metabolism is deliberately excluded. That belongs to the mitochondrial pillar and to the cancer-metabolism literature. What this article owns is host metabolism — the systemic state in which a tumour grows.
Part 1 — Five diseases, one architecture
The diseases in the title are usually taught separately. They share a common structure: a tissue exceeds its capacity to store, oxidise or clear a substrate, and the excess is redirected into a compartment where it is harmful.
| Disease | Tissue that lost control | Currency | Accepted readout | The artefact that mimics it |
|---|---|---|---|---|
| Obesity | Adipose storage capacity | Fatty acids, triglyceride | Body composition, adipocyte size distribution | Weight gain without adipose expansion (fluid, tumour, oedema) |
| Type 2 diabetes | Muscle disposal, hepatic output, beta cell | Glucose | Clamp-derived tissue-specific sensitivity | Fasting glucose alone (compensated states look normal) |
| MASH | Hepatocyte lipid handling and export | Triglyceride, free cholesterol, ceramide | Histology with fibrosis stage; imaging for fat | Elevated ALT without steatohepatitis |
| Cancer (host) | Systemic nutrient availability and signalling | Glucose, insulin, amino acids, lipids | Tumour incidence and latency in a defined metabolic state | Xenograft growth, which removes the host variable |
| Immunometabolism | Immune cell substrate use during activation | Glucose, glutamine, fatty acids | Function (killing, cytokine output) under defined substrates | Extracellular acidification rate in polarising medium |
Important distinction. The fourth row is the one most often mis-specified. A xenograft in a lean, young, immunodeficient mouse is not a model of obesity-associated cancer, no matter how the tumour is genetically labelled — the variable of interest is absent from the system.
Part 2 — Insulin resistance is not one thing
Insulin does at least four things that can fail independently, and they fail at different rates in the same patient.
| Process | Tissue | What resistance looks like | Decisive readout |
|---|---|---|---|
| Glucose disposal | Skeletal muscle, adipose | Reduced uptake at a given insulin concentration | Hyperinsulinaemic–euglycaemic clamp with tracer |
| Glucose output | Liver | Failure to suppress gluconeogenesis | Clamp with glucose tracer; hepatic glucose production |
| Lipolysis | Adipose | Failure to suppress free fatty acid release | Suppression of palmitate flux during clamp |
| Lipogenesis | Liver | Often not resistant; may be increased | De novo lipogenesis, triglyceride secretion |
| Vasodilation, protein synthesis | Endothelium, muscle | Reduced capillary recruitment, reduced synthesis | Not routinely measured |
The fourth row is the finding that reorganises the field. In established insulin resistance, hepatic glucose production stays high while hepatic lipogenesis remains insulin-sensitive or is increased. This is why the same patient can have fasting hyperglycaemia and a fatty liver, and why improving glycaemia does not automatically improve steatosis. Any claim of the form "insulin resistance causes X" should specify which of these processes is meant.
Readout note. HOMA-IR is a population index built from fasting glucose and insulin. It estimates hepatic insulin sensitivity reasonably in cohorts and poorly in individuals, and it cannot distinguish the rows above. The clamp is the reference method precisely because it fixes the glucose concentration and varies insulin, which is the experiment the index is a proxy for.
Caveat on compensation. Beta cell function can mask insulin resistance for years: fasting glucose stays near normal while insulin rises. A study that selects participants by fasting glucose therefore selects for beta cell failure as much as for insulin resistance, and a "normal" control group may contain resistant individuals with intact secretion.
Part 3 — Obesity is a storage problem, not a mass problem
The expandability model states the useful version of obesity: the risk comes from the ratio of lipid load to adipose storage capacity, not from mass itself.
| Observation | Interpretation under expandability | Alternative that also fits |
|---|---|---|
| Subcutaneous fat increased, insulin sensitivity preserved | Storage capacity adequate | Confounding by fitness or youth |
| Visceral fat increased | Capacity exceeded in the protective depot | Different venous drainage and lipolytic tone |
| Ectopic lipid in liver and muscle | Overflow into non-storage tissue | Primary defect in that tissue's oxidation |
| Adipocyte size increased without number | Hypertrophy at the limit of expansion | Impaired adipogenesis from another cause |
Important distinction. Subcutaneous and visceral adipose are not the same tissue in different places. They differ in developmental origin, venous drainage, lipolytic responsiveness and inflammatory profile. Reporting "fat mass" collapses that distinction, and reporting BMI collapses it further — BMI cannot distinguish a muscular lean individual from a small, hyperplastic, healthy adipose organ.
Readout note. Adipocyte size distribution is more informative than total fat mass, because hypertrophy at fixed number and hyperplasia at fixed size have different metabolic consequences. Collagenase-based isolation biases against large adipocytes, so a measured distribution is always a distribution of recoverable cells.
Part 4 — MASH: the readout problem is the field's problem
Metabolic dysfunction-associated steatohepatitis is defined histologically, and almost everything measured in the clinic is not histology.
| Readout | What it measures | What it misses |
|---|---|---|
| Liver fat (MRI-PDFF, MRS) | Triglyceride content | Inflammation, ballooning, fibrosis; a pure steatosis can have high fat |
| ALT | Hepatocyte leakage | Disease activity — ALT can be normal with advanced MASH |
| NAS score | Steatosis, lobular inflammation, ballooning | Fibrosis, which drives outcome; weights are arbitrary |
| Fibrosis stage | Architectural remodelling | Activity; a burnt-out cirrhosis scores high with little inflammation |
| ELF, FIB-4 | Indirect fibrosis estimates | Intermediate stages, where trials enrol |
Important distinction. Steatosis and steatohepatitis are different diseases that coexist. The lipid pillar established that total triglyceride is the least informative lipid measurement; the disease-level consequence is that a drug which lowers liver fat may do so by blocking esterification, which can worsen the toxic species rather than reduce them.
Caveat on mouse models. Dietary models reliably produce steatosis, variably produce inflammation, and inconsistently produce fibrosis. Genetic obesity models add weight but not necessarily fibrosis. This matters because a claim about MASH reversal is usually a claim about fibrosis, and fibrosis is the feature the models reproduce least. A study reporting improvement in steatosis and inflammation in a model without fibrosis has not tested the outcome it is named after.
Part 5 — Cancer: the host is the variable
The tumour-cell-intrinsic view — proliferation requires biosynthetic flux — is covered elsewhere. The disease-level question is different: which systemic state promotes tumour initiation and progression, and by what mechanism?
| Candidate mechanism | Prediction | Discriminating evidence |
|---|---|---|
| Hyperinsulinaemia | Reducing insulin signalling reduces tumour growth without changing glucose | Tissue-specific insulin receptor loss; insulin clamping |
| IGF-1 availability | Similar to above, acting through a different receptor | IGF-1 neutralisation separate from insulin |
| Adipokine signalling (leptin, adiponectin) | Effects track adipose function, not mass | Adipose-specific manipulations |
| Chronic inflammation | Effects track inflammatory tone, not adiposity | Immune depletion; cytokine neutralisation |
| Substrate surplus (glucose, fatty acids, amino acids) | Effects track substrate concentration | Direct substrate clamping at constant insulin |
Important distinction. Glucose is the intuitive mechanism and usually the weakest one. The epidemiological association between obesity and cancer is consistent for a subset of cancers — endometrial, oesophageal adenocarcinoma, colorectal, postmenopausal breast, renal and hepatic — and the mechanisms most consistently supported involve insulin signalling, sex steroids and inflammation rather than glucose concentration. A claim that "high glucose fuels tumour growth" needs a glucose clamp at fixed insulin, not a correlation between fasting glucose and outcome.
Caveat on cachexia. Cancer-associated weight loss is not the mirror image of obesity. It combines adipose loss, skeletal muscle loss and inflammation, and body weight can be stable while composition changes substantially. Weight as a readout will miss it; body composition will not.
Part 6 — Immunometabolism: activation state is the variable
Immune cells restructure their metabolism on activation, and the field's shorthand — effector T cells glycolytic, memory T cells oxidative, M1 macrophages glycolytic, M2 oxidative — describes culture conditions more reliably than tissue states.
| Population | Metabolic feature usually reported | What the assay actually fixes |
|---|---|---|
| Effector CD8 T cell | Glycolytic flux, glutamine use | The stimulation protocol and the medium |
| Memory CD8 T cell | Fatty acid oxidation, spare respiratory capacity | The IL-15 culture period |
| LPS-polarised macrophage | Glycolysis, succinate, HIF-1α | One TLR ligand, one timepoint |
| IL-4-polarised macrophage | OXPHOS, FAO | One cytokine, supraphysiological dose |
| Tumour-associated macrophage | Mixed; often suppressed | Dissociation and sorting stress |
Important distinction. M1 and M2 are stimulation artefacts with useful biology attached. In tissue, macrophages occupy a continuum, and a tumour-associated macrophage can be glycolytic in some regions and oxidative in others. A polarisation marker panel therefore reports the stimulus, not the state of the cell in the disease.
Caveat on 2-deoxyglucose. 2-DG inhibits hexokinase and thereby glycolytic flux, but it also depletes intermediates for N-linked glycosylation, which affects cytokine processing and secretion independently of ATP. A result of the form "glycolysis is required for IL-1β release, because 2-DG blocks it" therefore needs a second, non-glycolytic readout of the same step.
Readout note. Extracellular acidification measures proton export, not lactate, and in polarising medium the respiratory contribution to acidification is not constant. Immune function — killing, cytokine output, proliferation — is the endpoint a disease claim requires; the metabolic measurement explains it and does not replace it.
Part 7 — Cross-disease decision matrix
| Question | Tissue and timescale | Decisive readout | Practice that cannot support the claim |
|---|---|---|---|
| Is this insulin resistance or beta cell failure? | Muscle/liver over weeks | Clamp plus secretion index | Fasting glucose alone |
| Is this obesity or metabolic dysfunction? | Adipose over months | Body composition plus adipocyte size | Body weight |
| Is this steatohepatitis or steatosis? | Liver over months | Histology with fibrosis stage | Liver fat or ALT |
| Does this systemic state promote tumour growth? | Host over months | Tumour incidence in a defined metabolic state | Xenograft in a lean host |
| Is this immunometabolic reprogramming? | Immune population over hours | Function under defined substrates | Seahorse on polarising day 6 |
| Is this reversal or compensation? | Whole organism over weeks | Restoration of the set point, not the symptom | Normalisation of one analyte |
Part 8 — What a disease model has to reproduce
Seven requirements, in the order they are usually skipped.
- The set point shift, not just the acute perturbation. A single injection of a substrate models an excursion; the disease is the shifted baseline that persists between excursions.
- Diet composition, reported in full. Percentage of kilocalories from fat is not enough: fatty acid composition, sucrose and fructose content, and the supplier change the phenotype. Two "60% HFD" studies are not the same experiment.
- Housing temperature. Mice are housed near 22 °C, which is below their thermoneutral zone; they are chronically cold, which raises energy expenditure and alters adipose and immune phenotypes. Studies that do not report housing temperature have an uncontrolled variable that acts on the exact tissue being studied.
- Body composition, not weight. Fat and lean mass respond differently to almost every intervention.
- Pair-feeding where the question is composition rather than quantity. Without it, a dietary effect cannot be separated from reduced intake.
- Sex and littermate controls. Metabolic phenotypes are sexually dimorphic in mice as in humans, and different litters carry different microbiota.
- Time of day of sampling. Glucose tolerance, insulin sensitivity and corticosterone all vary across the light cycle; a single morning timepoint is a timepoint, not a baseline.
Part 9 — Failures that recur
- • Reading a whole-body number as a tissue mechanism. A normal fasting glucose is compatible with high hepatic output and high muscle disposal.
- • Using an acute stimulus to model a chronic set point. Twenty-four hours of palmitate is not insulin resistance.
- • Treating a lipid-lowering effect as a therapeutic effect. Blocking esterification lowers liver fat and can raise the toxic species.
- • Selecting controls by a variable that is part of the disease. "Normoglycaemic" controls in a diabetes study are selected for preserved secretion.
- • Xenograft models used to test host-level hypotheses. The host variable is removed by design.
- • Polarisation markers read as in vivo states. The stimulus is what was measured.
- • Seahorse endpoints substituted for immune function. Metabolic phenotype without a functional readout is a description.
- • Fibrosis claims in models without fibrosis. The named outcome was never present.
Part 10 — Where this connects
- • Glucose pillar supplies the flux rules: consumption, lactate release and oxygen consumption are three measurements, and none is a flux by default.
- • Lipid pillar supplies the species rules: total triglyceride is the least informative lipid measurement, and esterification is protective.
- • Amino acid pillar supplies the nitrogen rules: glutamine carries four roles, and withdrawal removes all of them.
- • Mitochondrial pillar supplies the organelle rules: lactate export coexists with intact OXPHOS, and dependency is medium-dependent.
- • Downstream, this layer connects to the stress domain: lipotoxicity, ER stress, inflammasome activation and cell-fate decisions are the mechanisms through which a metabolic set point becomes tissue injury.
Scope note
This article describes evidence standards for disease-level metabolic claims. It does not review clinical trial results, does not recommend any therapy, and does not constitute a statement about the safety or efficacy of any intervention. Epidemiological associations are described qualitatively; where a mechanism is contested, the contest is stated rather than resolved.
Scientific interpretation and experimental design
- • A disease claim needs a tissue, a flux and a timescale. Name all three before choosing a readout.
- • Insulin resistance is selective. Hepatic glucose output and hepatic lipogenesis can move in opposite directions.
- • HOMA-IR is an index, not a measurement. It cannot substitute for a clamp when the question is tissue-specific.
- • Obesity risk tracks storage capacity, not mass. Report body composition and adipocyte size.
- • Steatosis is not steatohepatitis. ALT and liver fat cannot stand in for histology with fibrosis.
- • Host metabolism is the variable in obesity-associated cancer. A lean xenograft host removes it.
- • Polarisation is a stimulus, not a state. Immune claims need a functional readout.
- • Housing temperature and diet composition are variables, not husbandry details.
Selected references for further reading
- • Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiological Reviews. 2018;98:2133–2223.
- • Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nature Medicine. 2017;23:804–814.
- • Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome. Biochimica et Biophysica Acta. 2010;1801:338–349.
- • Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell. 2014;156:20–44.
- • Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018;24:908–922.
- • Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, Karin M. Preclinical models for studying NASH-driven HCC: how useful are they? Cell Metabolism. 2019;29:18–26.
- • Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542:177–185.
- • O'Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nature Reviews Immunology. 2016;16:553–565.
- • Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017;169:570–586.
- • Maloney SK, Fuller A, Mitchell D, Gordon C, Overton JM. Translating animal model research: does it matter that our rodents are cold? Physiology. 2014;29:413–420.
- • Speakman JR. Use of high-fat diets to study rodent obesity as a model of human obesity. International Journal of Obesity. 2019;43:1491–1492.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »